HOPE-3, BP treatment, milestones in CV prevention

Dr. Salim Yusuf in an interview with Dr. Akbar Panju and Dr. Roman Jaeschke

Dr. Salim Yusuf, MD (BANGALORE), DPHIL (OXFORD), MRCP
Professor at the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Director at the Population Health Research Institute; his academic interests include societal, biologic, and genetic determinants of population health in developing populations

Dr. Akbar Panju, MB CHB, FRCPC
Professor and Acting Chair at the Department of Medicine, McMaster University, Hamilton, Ontario, Canada; previous Chief of Medicine at Hamilton Health Sciences; Medical Director of the Medard DeGroote Institute for Pain Research and Care; his academic interests are cardiology and thrombosis with a particular focus on chest pain; recipient of multiple teaching and scholarly awards; author or coauthor of over 60 articles in peer-reviewed journals

Salim Yusuf: We tested in this trial the role of lipid lowering with a statin and blood-pressure (BP) lowering with a low-dose combination of candesartan and thiazide. The concept behind it is that the association between lipids and cardiovascular disease, or BP and cardiovascular disease, is graded with no threshold, yet most of the trials were done only in those with either high risk, high lipid levels, or high BP levels. There is a graded association between BP and lipids versus cardiovascular disease, but most of the trials were done in people with high risk, high BP, or high lipid levels.

Part I: Heart Outcomes Prevention Evaluation (HOPE)-3 trial
Akbar Panju: Professor Yusuf, you are a world-renowned researcher in cardiovascular disease. What you have taught us over the last 2 decades has changed the way we practice cardiovascular medicine, which has led to saving a lot of lives around the world. These past few days, you had 3 articles published in a leading medical journal, the New England Journal of Medicine. I am going to ask you some questions about these articles. First, Professor Yusuf, what led to doing those trials?
However, the majority of cardiovascular disease, though, affects other people, so we wanted to test whether lowering lipid levels in people without cardiovascular disease but with average lipid levels or lowering BP in those with an average BP and at average risk would be beneficial.

Roman Jaeschke: You described the concept of those trials, or of this trial. What were the results?

SY: There were 3 main findings. The first was that statins, which lowered low-density lipoprotein (LDL) cholesterol levels, were beneficial irrespective of the starting level of LDL cholesterol, irrespective of any clinical criteria, which meant that almost everybody in the trial benefited from statins, and there was a 25% risk reduction of cardiovascular events.

With BP lowering, we saw no overall benefit. The benefit was seen, though, clearly in those in the upper third of BP range, which is the hypertension range; it was neutral in the middle range; and it tended to be harmful in those with the lowest BP. This is consistent with the external data—the findings from both the LDL-lowering part and the blood pressure-lowering part.

There was a group that received combined lipid lowering and BP lowering versus neither. In this group, if a person was hypertensive and you gave both statins as well as BP lowering, there was a 40% risk reduction, which is substantial. But if a patient was not hypertensive, using a statin alone gave you the entire benefit, which is about 30%.

The results of the study are important because the approach that we used was simple: no dose titration, single-fix doses, very little monitoring or very infrequent monitoring, and no LDL or blood levels that were required to get into the study. The study has huge implications because it means a majority of people in middle age who have 1 risk factor—which most people do—will benefit from statins, and if they have high BP, you would lower BP as well. Equally, one of the things that the hypertension guidelines do is they stress lowering BP, which is appropriate, but they do not stress that you should add a statin. This emphasizes that BP lowering and the statin together are important for hypertension.

RJ: Describing the results you actually keep coming to statins, even though one of the major components was the BP.

SY: Absolutely. Even if you have hypertension, statin is as important as BP lowering.

RJ: So that is quite a new concept and practice-changing finding.

SY: There has been one previous trial that reported similar findings, the ASCOT study. So the two together reinforce each other.

Part II: Blood pressure treatment thresholds and targets RJ: There was a whole number of papers or meta-analyses recently, which made people a little bit confused, I suspect. We have seen a meta-analysis of BP treatment in diabetes, which showed that aiming at a BP less than 140 mmHg or starting BP at 140 mmHg was actually harmful. Your data, you mentioned lowest, middle, and upper BP ranges?

SY: They are qualitatively similar in that in people with a BP below 140 mmHg there was no benefit, in people below 130 mmHg systolic BP there was a trend towards harm, and in those in the classic hypertension range there was benefit. So our results are consistent with prior data.

RJ: How would you reconcile it with the results of the SPRINT trial, which told us to target 120 mmHg or less?

SY: There were important differences in the populations included. The SPRINT trial first included people who already had severe hypertension and were already on 2 drugs before they got into the trial. And the question they therefore asked was: Should we be more aggressive?

The second thing is, they were high-risk people, with a risk that was twice the risk of the HOPE-3 populations. Twenty percent had vascular disease, another 30% had end-organ damage, so they were high-risk people. The results of the SPRINT trial must also be taken in the context of 2 things. One is the side effects: there were a lot of side effects in SPRINT, including emergency room visits and hospitalizations for acute kidney injury, so the SPRINT approach is less practical for the average patient. The second aspect of SPRINT is, you have to take it in the context of the ACCORD study in diabetics, which had a similar design but did not show the same level of benefit. There was a nonsignificant trend. There is a third trial, the stroke prevention study 3 (SPS3) that Dr. Robert Hart and Dr. Oscar Benavente did, which also had a similar level of BP lowering as SPRINT or ACCORD. That too only had a modest effect that was not statistically significant.

So if you take the totality of the evidence, SPRINT is a bit of an outlier. I believe the direction of benefit is right but the size of the benefit may be exaggerated. And there are some curious things about SPRINT that require explanation. First, there was a very little effect on reduction of stroke, and stroke is the most sensitive endpoint to BP lowering, so you wonder why. The second thing is, not only was there a reduction in cardiovascular disease deaths, which is expected and plausible, but there was also a reduction in noncardiovascular disease deaths, which has not been seen in other trials; this means perhaps the trial results were exaggerated by the play of chance. My reading: if you take SPRINT, ACCORD, other trials all put together with aggressive BP lowering, in high-risk people
there is a modest additional benefit, but the benefit is perhaps half the size that SPRINT showed.

**RJ:** So if I were to translate it, if you had a patient with a BP persistently around 140 mmHg, which is the current threshold to recognize hypertension, without many risk factors you would probably say...

**SY:** Leave them alone if they have no other risk factors and advice weight reduction and other lifestyle modification. But if they have any risk factor, consider adding antihypertensive drugs as well.

**RJ:** And the more risk factors they have, the earlier you will start to treat?

**SY:** Exactly. If there is either vascular disease or more risk factors then treat them earlier, but in all of them use a statin.

**RJ:** That is very practical, thank you.

### Part III: Milestones of cardiovascular prevention

**RJ:** Professor Yusuf, you have been in the forefront of cardiovascular prevention for the last 20 or 30 years. Would you comment about the milestones that you observed through those years? You mentioned to us that cardiovascular mortality is lowered by half within our lifespan.

**SY:** A single milestone is hard to say but I think there are 2 or 3 collective landmarks that have made a big impact. The first is that we have excellent epidemiologic data that clearly show tobacco is bad for you—and tobacco is really, really bad; it is the biggest killer in the world. Second is, we know that elevated BP is a bad risk factor, so is lipids, and this came from robust epidemiological studies. So the epidemiological studies were the starting point.

Then we tested the hypotheses in trials, and it is the collectivity of the evidence from several trials that was persuasive, not just 1 or 2 trials alone (in most instances). There are about 25 trials on statins with lipid lowering and most of them are consistent. There are just as many trials on BP lowering. While they seem to differ in slight ways, overall the totality of the evidence shows benefit.

Conceptually, the 2 milestones I would say were the large epidemiology and the large trials. It is a mixture of these 2 methods. Of course, you need drugs to lower BP, and so good pharmacology, which involves much fundamental science, led to greater benefit. So it was a confluence of all these approaches that came about, and you might call that confluence evidence-based medicine—others may call it another name. I think the reduction in cardiovascular disease is a testimony to these combined efforts.

### McMaster Perspective

This interview is part of the McMaster Perspective collection. The video can be viewed at www.mcmastertextbook.com. Published with modifications with permission from Dr. Salim Yusuf and Dr. Akbar Panju.


### REFERENCES